StockData
Absci Corp logo

Absci Corp (ABSI) company profile

ABSINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$7.58+0.11 (+1.40%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

About Absci

Services-Commercial Physical & Biological Research, SIC 8731

Absci Corporation is a clinical-stage biopharmaceutical company that designs and develops differentiated antibody therapeutics using an artificial intelligence platform integrated with laboratory testing. Its operations include an internal pipeline of drug candidates as well as partnered discovery programs. The company’s lead investigational therapeutic, ABS-201, targets prolactin receptor signaling to treat androgenetic alopecia and endometriosis. Absci also develops additional antibody programs, such as ABS-101, alongside early-stage oncology and immunology candidates. The firm collaborates with external pharmaceutical and biotechnology companies, offering AI-guided antibody discovery, de novo protein design, and lead optimization services to support partners' development pipelines.

The company conducts operations utilizing a combined wet-laboratory and dry-laboratory facility that spans more than 77,000 square feet. Its clinical development activities include multi-site clinical trials in Australia for its lead therapeutic candidate, while its business partnerships involve multinational pharmaceutical enterprises. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Absci's latest annual report, written by StockData.

Company profile

Company

Legal name
Absci Corp
Headquarters
Vancouver, WA
Address
18105 Se Mill Plain Blvd 98683
Phone
(360) 949-1041
Website
absci.com
Employees
140, Dec 31, 2025
Industry
Services-Commercial Physical & Biological Research
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Jose, California

Stock & identifiers

Ticker
ABSI
Exchange
Nasdaq
IPO date
Jul 23, 2021
Shares outstanding
172M, Jul 31, 2026
Public float
$303.80M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1672688
CUSIP
00091E109
ISIN
US00091E1091
FIGI
BBG011N54CJ8
Share class FIGI
BBG011N54DC3
EIN
85-3383487

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sean McClainChief Executive Officer, Director10,822,389
Todd BedrickSVP, CAO199,128
Zachariah JonassonCFO / CBO484,918
Ransi Mudalinayake SomaratneCMO, Head of R&D–
Andreas BuschChief Innovation Officer421,446
Shelby J. WalkerChief Legal Officer139,775
Mary T. SzelaDirector21,300
Karen K. McGinnisDirector48,420
Menelas N. PangalosDirector242,408
Daniel A. RabinovitsjDirector33,420
Joseph SiroshDirector33,420
Houten Frans VanDirector73,420

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Sean McClain
President, Founder and Chief Executive Officer
$689.94K$650.48K$1.96M$372.57K$14.00K$3.69M-62%
Zachariah Jonasson, Ph.D.
Chief Financial Officer and Chief Business Officer
$553.45K$650.48K$839.80K$249.05K$14.00K$2.31M-19%
Andreas Busch, Ph.D.
Chief Innovation Officer*
$712.80K$81.05K$239.42K$384.91K$142.95K$1.56M-41%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 23, 2021
Offer price
$16.00
Securities offered
12,500,000
Gross proceeds
$200.00M
Exchange
Nasdaq
First trading day
Jul 22, 2021
First-day close
$21.59+34.9%
Lock-up ends (est.)
Jan 18, 2022

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 140 employees, many of whom have advanced post-graduate degrees, primarily engaged in research and development and general and administrative functions.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 23, 2021IPOInitial public offering priced (424B4 prospectus)
Jul 21, 2021ListingRegistration of securities on an exchange (Form 8-A)
Dec 19, 2019Name changeName changed from AbSci, LLC to Absci Corp

See a number that looks wrong?